Edition:
United States

OpGen Inc (OPGN.OQ)

OPGN.OQ on NASDAQ Stock Exchange Capital Market

2.05USD
20 Apr 2018
Change (% chg)

$-0.13 (-5.96%)
Prev Close
$2.18
Open
$2.10
Day's High
$2.19
Day's Low
$1.95
Volume
161,539
Avg. Vol
87,525
52-wk High
$28.00
52-wk Low
$1.62

Latest Key Developments (Source: Significant Developments)

Opgen Reports Q4 Loss Per Share $1.33
Thursday, 15 Mar 2018 04:05pm EDT 

March 15 (Reuters) - Opgen Inc ::OPGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE.Q4 REVENUE $1.0 MILLION VERSUS $1.0 MILLION.Q4 LOSS PER SHARE $1.33.  Full Article

Opgen Says Collaborating With Beth Israel Deaconess Medical Center In Boston
Tuesday, 13 Mar 2018 07:30am EDT 

March 13 (Reuters) - Opgen Inc ::OPGEN ANNOUNCES COLLABORATOR IN VERIFICATION STUDY FOR ACUITAS® TEST.OPGEN INC - ‍COLLABORATING WITH BETH ISRAEL DEACONESS MEDICAL CENTER IN BOSTON ON A VERIFICATION STUDY FOR OPGEN'S ACUITAS TEST​.  Full Article

OpGen Says ‍Entered Agreement To Use Thermo Fisher's Real-Time PCR Technology In Co's New Acuitas Tests​
Tuesday, 13 Feb 2018 07:30am EST 

Feb 13 (Reuters) - Opgen Inc ::OPGEN INC - ‍ENTERED GLOBAL SUPPLY AGREEMENT TO USE THERMO FISHER SCIENTIFIC'S REAL-TIME PCR TECHNOLOGY IN COMPANY'S ACUITAS AMR GENE PANEL TESTS​.OPGEN INC - ‍PLANNING CLINICAL TRIALS TO SUPPORT REGULATORY SUBMISSIONS FOR BROADER CLINICAL USE IN PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS​.  Full Article

Opgen reports 2017 third quarter financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Opgen Inc ::Opgen reports 2017 third quarter financial results and provides business update.Q3 loss per share $0.07.Q3 revenue $745,000 versus $760,000.  Full Article

OpGen Q2 loss per share $0.15​
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - OpGen Inc :OpGen reports 2017 second quarter financial results and provides business update.Q2 revenue $700,000 versus $1.2 million.OpGen Inc qtrly ‍net loss per common share, basic and diluted, $0.15​.OpGen - ‍first of rapid tests expected to be tested at third-party clinical evaluation sites in q4 and launched as an ruo test in first half of 2018​.OpGen Inc - ‍cash and cash equivalents were $0.2 million as of June 30, 2017 compared with $4.1 million as of december 31, 2016​.OpGen Inc - ‍expect a decrease in operating expenses of approximately 25% to 30% in second half of 2017​.  Full Article

Opgen Acuitas MDRO gene test approved by NY State Department Of Health
Wednesday, 12 Jul 2017 01:28pm EDT 

July 12 (Reuters) - Opgen Inc :Opgen acuitas® mdro gene test approved by ny state department of health.Opgen inc says new york state department of health has approved acuitas mdro gene test for use by physicians and healthcare providers in state.  Full Article

Opgen files for offering up to 13.7 mln shares of co's common stock
Thursday, 29 Jun 2017 06:18am EDT 

June 29 (Reuters) - Opgen Inc ::Opgen Inc files for offering up to 13.7 million shares of co's common stock and common warrants to purchase aggregate of 6.85 million shares of co's common stock.  Full Article

Opgen Qtrly net loss per common share $0.19
Wednesday, 26 Apr 2017 04:00pm EDT 

April 26 (Reuters) - Opgen Inc ::Opgen announces 2017 first quarter financial results.Q1 revenue $800,000 versus $1.1 million.Qtrly net loss per common share - basic and diluted $0.19.  Full Article

OpGen announces Q4 revenue of $1 mln
Thursday, 23 Mar 2017 04:01pm EDT 

OpGen Inc : OpGen announces 2016 fourth quarter and year end financial results . Q4 revenue fell 24 percent to $1.0 million .OpGen Inc qtrly loss per share $0.21.  Full Article

OpGen sees 24 pct fall in Q4 revenue
Thursday, 26 Jan 2017 05:27pm EST 

OpGen Inc - : Total revenue for Q4 of 2016 is expected to be approximately $1.0 million, a decrease of approximately 24% .Net loss for Q4 of 2016 is expected to be in range of approximately $4.6 million and $5.1 million.  Full Article

BRIEF-Opgen Reports Q4 Loss Per Share $1.33

* OPGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE